Psychedelic drug developers could benefit from NIH funding for chronic pain

seekingalpha04-30

The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431081171?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg","is_english":true,"pubTime":"2024-04-30 01:37","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2431081171","market":"sh","top_or_hot":-1,"title":"Psychedelic drug developers could benefit from NIH funding for chronic pain","media":"seekingalpha","content":"<div>\n<p>The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Psychedelic drug developers could benefit from NIH funding for chronic pain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPsychedelic drug developers could benefit from NIH funding for chronic pain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 01:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATAI","symbol_name":"ATAI Life Sciences B.V.*","start_time":0,"source_url":"https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain","article_id":"2431081171","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431081171","pubTimestamp":1714412227,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, said that the research can include psilocybin , LSD, mescaline, and MDMA, also known as ecstasy.  \"A potential novel approach to treatment of chronic pain in adults involves psychedelic-assisted therapy ,\" the notice states. \"Evidence for the efficacy of PAT has been particularly notable in depression, anxiety , post-traumatic stress disorder , and substance use disorders, among other indications.\"  Marijuana Moment first reported the development on Monday. Several companies involved in developing psychedelic-based therapies could potentially benefit from the funding. These include Mind Medicine , Atai Life Sciences , Cybin , COMPASS Pathways , Lucy Scientific Discovery , 180 Life Sciences , Bright Binds Bioscience , and Seelos Theraspeutics .","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*","BK4139":"生物科技","CMPS":"COMPASS Pathways plc","BK4007":"制药","ATNF":"180 Life Sciences Corp","DRUG.AU":"BETASHARES GLOBAL HEALTHCARE","QID":"纳指两倍做空ETF","BK7095":"多种金属与采矿","LSDI":"Lucy Scientific Discovery, Inc.","BK4547":"WSB热门概念","PSQ":"纳指反向ETF","PAT.AU":"PATRIOT LITHIUM LTD","QQQ":"纳指100ETF","QLD":"纳指两倍做多ETF","DRUG":"Bright Minds Biosciences Inc","TQQQ":"纳指三倍做多ETF","BK4539":"次新股","SEEL":"Seelos Therapeutics Inc.","MNMD":"Mind Medicine (MindMed) Inc.","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite"},"translate_title":"迷幻药开发商可能受益于NIH对慢性疼痛的资助","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1,"ATNF":1,"SEEL":1,"CMPS":1,"DRUG":1,"DRUG.AU":1,"LSDI":1,"MNMD":1,"PAT.AU":1,".IXIC":0.9,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, said that the research can include psilocybin (the psychedelic compound found in \"magic mushrooms\"), LSD, mescaline, and MDMA, also known as ecstasy.  \"A potential novel approach to treatment of chronic pain in adults involves psychedelic-assisted therapy (PAT),\" the notice states. \"Evidence for the efficacy of PAT has been particularly notable in depression, anxiety (especially existential distress), post-traumatic stress disorder (PTSD), and substance use disorders, among other indications.\"  Marijuana Moment first reported the development on Monday. Several companies involved in developing psychedelic-based therapies could potentially benefit from the funding. These include Mind Medicine (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI), Cybin (NYSE:CYBN), COMPASS Pathways (NASDAQ:CMPS), Lucy Scientific Discovery (LSDI), 180 Life Sciences (ATNF), Bright Binds Bioscience (DRUG), and Seelos Theraspeutics (SEEL).","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431081171"}